Treatment of renal cell carcinoma: Current status and future directions

被引：685

作者：

Barata, Pedro C. ^{[1
]}

Rini, Brian I. ^{[2
,3
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[2] Cleveland Clin, Lerner Coll Med, Med, Cleveland, OH 44106 USA

[3] Cleveland Clin, Taussig Canc Inst, Genitourinary Program, Glickman Urol & Kidney Inst,Dept Hematol & Oncol, Cleveland, OH 44106 USA

来源：

CA-A CANCER JOURNAL FOR CLINICIANS | 2017年 / 67卷 / 06期

关键词：

clinical trials; immunotherapy; programmed death 1 (PD-1); renal cell carcinoma; targeted agents; vascular endothelial growth factor (VEGF); ENDOTHELIAL GROWTH-FACTOR; DOSE RECOMBINANT INTERLEUKIN-2; INTEGRATED STAGING SYSTEM; INITIAL TARGETED THERAPY; PHASE-III TRIAL; RADICAL NEPHRECTOMY; INTERFERON-ALPHA; OPEN-LABEL; DOUBLE-BLIND; HIGH-RISK;

D O I：

10.3322/caac.21411

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agentsincluding molecules against vascular endothelial growth factor, platelet-derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin and the MET and AXL tyrosine-protein kinase receptors; and an immune-checkpoint inhibitorhave been approved based on significant activity in patients with advanced RCC. Despite these advances, important questions remain regarding biomarkers of efficacy, patient selection, and the optimal combination and sequencing of agents. The purpose of this review is to summarize present management and future directions in the treatment of metastatic RCC. CA Cancer J Clin 2017;67:507-524. (c) 2017 American Cancer Society.

引用

页码：507 / 524

页数：18

共 167 条

[51] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].

Choueiri, Toni K. ;

Escudier, Bernard ;

Powles, Thomas ;

Tannir, Nizar M. ;

Mainwaring, Paul N. ;

Rini, Brian I. ;

Hammers, Hans J. ;

Donskov, Frede ;

Roth, Bruce J. ;

Peltola, Katriina ;

Lee, Jae Lyun ;

Heng, Daniel Y. C. ;

Schmidinger, Manuela ;

Agarwal, Neeraj ;

Sternberg, Cora N. ;

McDermott, David F. ;

Aftab, Dana T. ;

Hessel, Colin ;

Old, Christian Scheff ;

Schwab, Gisela ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2016, 17 (07) :917-927

[52] Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma [J].

Choueiri, Toni K. ;

Vaishampayan, Ulka ;

Rosenberg, Jonathan E. ;

Logan, Theodore F. ;

Harzstark, Andrea L. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Srinivas, Sandy ;

Stein, Mark N. ;

Adams, Laurel M. ;

Ottesen, Lone H. ;

Laubscher, Kevin H. ;

Sherman, Laurie ;

McDermott, David F. ;

Haas, Naomi B. ;

Flaherty, Keith T. ;

Ross, Robert ;

Eisenberg, Peter ;

Meltzer, Paul S. ;

Merino, Maria J. ;

Bottaro, Donald P. ;

Linehan, W. Marston ;

Srinivasan, Ramaprasad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :181-186

[53] The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy [J].

Choueiri, Toni K. ;

Xie, Wanling ;

Kollmannsberger, Christian ;

North, Scott ;

Knox, Jennifer J. ;

Lampard, J. Geoffrey ;

McDermott, David F. ;

Rini, Brian I. ;

Heng, Daniel Y. C. .

JOURNAL OF UROLOGY, 2011, 185 (01) :60-66

[54] Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].

Clark, JI ;

Atkins, MB ;

Urba, WJ ;

Creech, S ;

Figlin, RA ;

Dutcher, JP ;

Flaherty, L ;

Sosman, JA ;

Logan, TF ;

White, R ;

Weiss, GR ;

Redman, BG ;

Tretter, CPG ;

McDermott, D ;

Smith, JW ;

Gordon, MS ;

Margolin, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140

[55] The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy [J].

Clark, Peter E. .

KIDNEY INTERNATIONAL, 2009, 76 (09) :939-945

[56] The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer [J].

Collinson, Fiona J. ;

Gregory, Walter M. ;

McCabe, Chris ;

Howard, Helen ;

Lowe, Catherine ;

Potrata, DrBarbara ;

Tubeuf, Sandy ;

Hanlon, Pat ;

McParland, Lucy ;

Wah, T. ;

Selby, Peter J. ;

Hewison, Jenny ;

Brown, Julia ;

Brown, Janet .

BMC CANCER, 2012, 12

[57] Can We Better Select Patients With Metastatic Renal Cell Carcinoma for Cytoreductive Nephrectomy? [J].

Culp, Stephen H. ;

Tannir, Nizar M. ;

Abel, E. Jason ;

Margulis, Vitaly ;

Tamboli, Pheroze ;

Matin, Surena F. ;

Wood, Christopher G. .

CANCER, 2010, 116 (14) :3378-3388

[58] A four-gene signature predicts survival in clear-cell renal-cell carcinoma [J].

Dai, Jun ;

Lu, Yuchao ;

Wang, Jinyu ;

Yang, Lili ;

Han, Yingyan ;

Wang, Ying ;

Yan, Dan ;

Ruan, Qiurong ;

Wang, Shaogang .

ONCOTARGET, 2016, 7 (50) :82712-82726

[59] Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial. [J].

Dorff, Tanya B. ;

Longmate, Jeff ;

Pal, Sumanta Kumar ;

Stadler, Walter Michael ;

Fishman, Mayer N. ;

Vaishampayan, Ulka N. ;

Rao, Amol Rajeev ;

Hu, James ;

Quinn, David I. ;

Lara, Primo .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[60] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

← 1 2 3 4 5 6 7 8 9 10 →